NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.

The firm will use the proceeds to advance its platform technology, R&D, and pre-commercialization activities for its base-editing drugs.

The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.

Cure51 and Assistance Publique – Hôpitaux de Paris have partnered to identify biomarkers for long-term survival in pancreatic cancer.

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

The firms are combining forces to get their cancer screening and diagnostic platforms into more hospitals in the US.

In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.

The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.

After a promising feasibility study showing the potential of its natural language processing models, MSK has ambitions to use them in patient care.